Ryvu Therapeutics to Support Clinical Trials for BioNTech in Poland

Ryvu Therapeutics, a clinical-stage drug discovery and development company specializing in novel therapies targeting emerging oncology targets, is entering a strategic partnership with BioNTech to benefit Polish cancer patients by providing support for trial site activation and patient recruitment for multiple investigational immunotherapies within BioNTech’s oncology pipeline in Poland.

Ryvu’s operational excellence, expertise in oncology clinical operations, and existing trial site network will be leveraged to streamline access of Polish patients to BioNTech’s investigational immunotherapies. BioNTech will design and conduct clinical trials for some of its priority programs in Poland and fund Ryvu’s services under the agreement. The clinical programs planned for inclusion in the agreement span various solid tumor types, including lung, breast, and colorectal cancer.

Kamil Sitarz, Chief Operating Officer, Management Board Member of Ryvu Therapeutics, said: “We are thrilled to build on our strong research relationship with BioNTech by entering a strategic agreement that leverages Ryvu’s operational excellence and expertise in oncology clinical operations to bring more BioNTech clinical programs to Poland.”